Stock CGON CG ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases CG Oncology, Inc.

Equities

CGON

US1569441009

Real-time Estimate Cboe BZX
Other stock markets
 11:29:57 2024-07-17 am EDT 		5-day change 1st Jan Change
37.75 USD +0.27% Intraday chart for CG Oncology, Inc. +18.35% 0.00%
Jun. 28 Sector Update: Health Care Stocks Decline in Late Afternoon Trading MT
Jun. 28 Sector Update: Health Care Stocks Edge Higher in Afternoon Trading MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Bladder Cancer Pipeline 2024 | UroGen Pharma Ltd., Asieris Pharmaceuticals, G1 Therapeutics, Inc., LintonPharm Co. Ltd., Vaxiion Therapeutics, Merck Sharp & Dohme LLC, CG Oncology Inc., Ferring Pharma
AQ
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
AQ
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
AQ
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
AQ
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
AQ
CG Oncology, Inc. - Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
AQ
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
AQ
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
AQ
CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting
AQ
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
AQ
CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGON Stock
  4. News CG Oncology, Inc.
  5. Press Releases